Biogen (NASDAQ:BIIB) Price Target Lowered to $213.00 at Wedbush

Biogen (NASDAQ:BIIB – Free Report) had its price objective reduced by Wedbush from $245.00 to $213.00 in a research report released on Wednesday morning, Benzinga reports. They currently have a neutral rating on the biotechnology company’s stock. Wedbush also issued estimates for Biogen’s Q1 2024 earnings at $3.25 EPS, Q3 2024 earnings at $4.13 EPS, […]

Related Keywords

United States ,Germany ,America ,Piper Sandler ,Erick Rowinsky ,Priya Singhal ,Wells Fargo Company ,Norden Group ,Securities Exchange Commission ,Cents Investing ,Biogen Company Profile ,Sumitomo Mitsui Trust Holdings Inc ,Denali Advisors ,Biogen Inc ,Legacy Wealth Asset Management ,Cantor Fitzgerald ,Free Report ,Wells Fargo ,Moderate Buy ,Get Free Report ,Exchange Commission ,Director Eric ,Wealth Asset Management ,Sumitomo Mitsui Trust Holdings ,Mitsui Trust Holdings ,Biogen Daily ,Biogen ,Nasdaq Biib ,Biib ,Medical ,09062x10 ,Lower Price Target ,Wedbush ,